Epirium Bio
- Website
- epirium.com
- Total Funding
- $85.0M
- Last Round
- $85.0M Series ADec 2019
- Rounds
- 1
About
Epirium Bio is a clinical-stage biopharmaceutical company developing orally bioavailable small molecules that promote mitochondrial biogenesis and function. Its IP-protected platform leverages PGE-2 signaling to restore tissue homeostasis, stimulate regeneration, and reduce fibrosis. Lead candidate MF-300 is in a Phase 2b sarcopenia study, while the company is exploring additional neuromuscular, inflammatory, and fibrotic indications.
Summary
Epirium Bio is a Biotech company. It has raised $85.0M in total across 1 round, most recently a $85.0M Series A round in Dec 2019. Investors include Longitude Capital, ARCH Venture Partners and Vertex Ventures HC.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Dec 2019
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/epirium-bio"><img src="https://indexed.vc/api/badge/company/epirium-bio" alt="Epirium Bio on Indexed.vc" width="260" height="76" /></a>